Amgen Hit With $50M Infringement Verdict Over Leukemia Drug
By Dani Kass · December 18, 2024, 6:18 PM EST
Germany's Lindis Biotech has persuaded a Delaware federal jury that Amgen should pay $50.3 million in damages for encouraging healthcare providers to infringe the Munich company's immunotherapy patents through administering the...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login